Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Value of Information of Secondary dAta in ONCOGEnetics (VISAGE-ONCO)

12. juli 2021 opdateret af: Centre Georges Francois Leclerc

VISAGE-ONCO study is a qualitative transversal study aiming to identify and describe processes and mechanisms that explain in cancerology the feelings and experience of patients and health professionals with regard to the possibility of having access to secondary findings generated by the use High-speed exome sequencing . Semi-structured interviews will be conducted with patients and health professionals to answer this aims from 2 situations.

The first situation is in the context of the standard practice for theranostic purposes, where somatic and constitutional analysis of the various genes involved in carcinogenesis is carried out systematically in parallel. Patients are informed that the analysis of these genes may reveal the existence of a genetic predisposition to another type of cancer than the one for which patients have consulted, with a risk for themselves or their relatives, which could modify their management. This targeted information on genetic predisposition genes to cancer is therefore provided as part of standard management for theranostic purposes, but without any detailed exploration of the reasons why patients wanted to be informed.

The second situation is in the framework exome analysis position in the strategy of genetic redisposition factors identification in early-onset cancer study (EX²TRICAN NCT04141462) where all the genes identified in human pathology are part of the analysis. Patients have the possibility of accessing a result concerning a gene that may or may not be linked to a hereditary cancer risk if patients have ticked off in the consent form the wish to be informed.

Therefore, two distinct questions arise:

  • That of understanding the wish of patients to be given back actionable data which can be identified in a fortuitous way within the framework of standard management for theranostic purposes and in EX²TRICAN, by taking into account the fact that these data can constitute an opportunity for the patient in terms of management; but patients also constitute a risk of transmission for they relatives, and a psychological risk by the anxiety generated;
  • The wish to have access - or not - to data which are not actively sought today within the framework of standard care for theranostic purposes and in EX²TRICAN (genetic alterations increasing the risk of cardiovascular or metabolic diseases), but which could be proposed in a systematic way in the future because of their actionable character.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Forventet)

70

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Sandrine DABAKUYO, PHD
  • Telefonnummer: 33 0345348067
  • E-mail: sdabakuyo@cgfl.fr

Studiesteder

      • Dijon, Frankrig
        • Rekruttering
        • Centre Georges François Leclerc
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • François GHIRINGHELLI, PU-PH

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients with cancer who will undergo exomes analysis

Beskrivelse

Inclusion Criteria:

Standard care patients for theranostic goal

  • Histological or cytological evidence of a diagnosis of metastatic or locally advanced solid tumor
  • Tumor material available and usable for the analyses required by the study
  • Request for genetic analysis to be performed at the initiation of the 1st or 2nd line of treatment
  • Normal biological parameters
  • Life expectancy ≥ 6 months
  • Performance status ≤ 1
  • Social security affiliation
  • Who have received information and agreed to participate

Patient from EX²TRICAN study

  • Histological or cytological evidence of a diagnosis of metastatic or locally advanced solid tumor
  • Having cancer before age 40
  • Patient affiliated to social security
  • Availability of a tumor sample if secondary functional studies are required
  • Availability of the 2 parents when the trio approach is required
  • Availability of affected relatives
  • Who have received information and agreed to participate

Health professional

  • To be oncologist or geneticist or genetic counselor and able to be inform, prescribe and transmit the results of secondary data
  • Working at university hospital center of dijon or cancerology center Georges Francois Leclerc at Dijon
  • Who have received information and agreed to participate

Exclusion Criteria:

Standard care patients for theranostic goal

  • History of Human immunodeficiency virus infection
  • History of Hepatitis B virus /Hepatitis C virus infection
  • To be pregnant or likely to be or breastfeeding disorders psychiatric

Patient from EX²TRICAN study

  • Minor index cases
  • Disorders psychiatric

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: Andet
  • Tidsperspektiver: Tværsnit

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Patient's experience through semi-structured interviews
Tidsramme: 1 day (during the interview)
Patients were asked during a semi-structured interview, to understand their feelings and experience ith regard to the possibility of having access to secondary findings
1 day (during the interview)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. december 2019

Primær færdiggørelse (Forventet)

9. juni 2022

Studieafslutning (Forventet)

9. december 2022

Datoer for studieregistrering

Først indsendt

28. juni 2021

Først indsendt, der opfyldte QC-kriterier

12. juli 2021

Først opslået (Faktiske)

22. juli 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. juli 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. juli 2021

Sidst verificeret

1. juli 2021

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2019-A02303-54

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .